Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:25:19 EST Tue 11 Nov 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:KRYS from 2024-11-12 to 2025-11-11 - 29 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2025-11-03 07:00U:KRYSNews ReleaseKrystal Biotech Announces Third Quarter 2025 Financial and Operating Results
2025-10-21 08:00U:KRYSNews ReleaseKrystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025
2025-10-14 08:00U:KRYSNews ReleaseKrystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis
2025-09-15 08:00U:KRYSNews ReleaseKrystal Biotech Announces FDA Approval of Updated VYJUVEK(TM) Label
2025-09-02 08:00U:KRYSNews ReleaseKrystal Biotech to Present at Cantor Global Healthcare Conference 2025
2025-08-21 12:12U:KRYSNews ReleaseKrystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer
2025-08-04 07:00U:KRYSNews ReleaseKrystal Biotech Announces Second Quarter 2025 Financial and Operating Results
2025-07-29 07:00U:KRYSNews ReleaseKrystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025
2025-07-25 09:00U:KRYSNews ReleaseKrystal Biotech Announces Approval of VYJUVEK(TM) by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
2025-07-24 08:00U:KRYSNews ReleaseJeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Decollete
2025-07-09 07:00U:KRYSNews ReleaseKrystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
2025-06-24 07:00U:KRYSNews ReleaseKrystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
2025-06-03 08:00U:KRYSNews ReleaseKrystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference
2025-05-07 08:00U:KRYSNews ReleaseKrystal Biotech to Present at BofA Securities 2025 Health Care Conference
2025-05-06 08:00U:KRYSNews ReleaseKrystal Biotech Announces First Quarter 2025 Financial and Operating Results
2025-04-28 07:00U:KRYSNews ReleaseKrystal Biotech Announces European Commission Approval of VYJUVEK(TM) for the Treatment of Dystrophic Epidermolysis Bullosa
2025-04-24 08:00U:KRYSNews ReleaseKrystal Biotech to Present at Upcoming Scientific Conferences
2025-04-17 08:00U:KRYSNews ReleaseKrystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025
2025-04-07 16:30U:KRYSNews ReleaseJeune Aesthetics Appoints Marc Forth as Chief Executive Officer
2025-02-28 07:40U:KRYSNews ReleaseKrystal Biotech Receives Positive CHMP Opinion for VYJUVEK(TM) for the Treatment of Dystrophic Epidermolysis Bullosa
2025-02-26 08:00U:KRYSNews ReleaseKrystal Biotech to Present at TD Cowen 45th Annual Health Care Conference
2025-02-19 07:00U:KRYSNews ReleaseKrystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results
2025-02-06 08:00U:KRYSNews ReleaseKrystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
2025-01-14 08:00U:KRYSNews ReleaseJeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer
2024-12-18 08:00U:KRYSNews ReleaseKrystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer
2024-12-12 08:00U:KRYSNews ReleaseKrystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels
2024-12-09 16:15U:KRYSNews ReleaseKrystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa
2024-11-27 07:00U:KRYSNews ReleaseKrystal Biotech to Present at Upcoming Investor Conferences
2024-11-12 07:00U:KRYSNews ReleaseKrystal Biotech to Present at Stifel 2024 Healthcare Conference